ArticleFrontiers in oncology2022

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel

An-Guo Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.